183 related articles for article (PubMed ID: 23755200)
21. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
Chételat G; Ossenkoppele R; Villemagne VL; Perrotin A; Landeau B; Mézenge F; Jagust WJ; Dore V; Miller BL; Egret S; Seeley WW; van der Flier WM; La Joie R; Ames D; van Berckel BN; Scheltens P; Barkhof F; Rowe CC; Masters CL; de La Sayette V; Bouwman F; Rabinovici GD
Brain; 2016 Sep; 139(Pt 9):2528-39. PubMed ID: 27357349
[TBL] [Abstract][Full Text] [Related]
22. Tracking Cognitive Decline in Amnestic Mild Cognitive Impairment and Early-Stage Alzheimer Dementia: Mini-Mental State Examination versus Neuropsychological Battery.
Kim J; Na HK; Byun J; Shin J; Kim S; Lee BH; Na DL
Dement Geriatr Cogn Disord; 2017; 44(1-2):105-117. PubMed ID: 28768247
[TBL] [Abstract][Full Text] [Related]
23. Impact of Differential Rates of Disease Progression in Amyloid-Positive Early Alzheimer's Disease: Findings from a Longitudinal Cohort Analysis.
Chandler J; Georgieva M; Desai U; Done N; Gomez-Lievano A; Ye W; Zhao A; Eid D; Hilts A; Kirson N; Schilling T
J Prev Alzheimers Dis; 2024; 11(2):320-328. PubMed ID: 38374738
[TBL] [Abstract][Full Text] [Related]
24. Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI.
Mukherjee S; Trittschuh E; Gibbons LE; Mackin RS; Saykin A; Crane PK;
Brain Imaging Behav; 2012 Dec; 6(4):649-60. PubMed ID: 23161456
[TBL] [Abstract][Full Text] [Related]
25. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.
Besser LM; Litvan I; Monsell SE; Mock C; Weintraub S; Zhou XH; Kukull W
Parkinsonism Relat Disord; 2016 Jun; 27():54-60. PubMed ID: 27089852
[TBL] [Abstract][Full Text] [Related]
26. Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases.
Corriveau-Lecavalier N; Barnard LR; Botha H; Graff-Radford J; Ramanan VK; Lee J; Dicks E; Rademakers R; Boeve BF; Machulda MM; Fields JA; Dickson DW; Graff-Radford N; Knopman DS; Lowe VJ; Petersen RC; Jack CR; Jones DT
Brain; 2024 Apr; 147(4):1483-1496. PubMed ID: 37831661
[TBL] [Abstract][Full Text] [Related]
27. Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia.
Xiong LY; Ouk M; Wu CY; Rabin JS; Lanctôt KL; Herrmann N; Black SE; Edwards JD; Swardfager W
Alzheimers Res Ther; 2021 Sep; 13(1):147. PubMed ID: 34479635
[TBL] [Abstract][Full Text] [Related]
28. Gait phenotype from mild cognitive impairment to moderate dementia: results from the GOOD initiative.
Allali G; Annweiler C; Blumen HM; Callisaya ML; De Cock AM; Kressig RW; Srikanth V; Steinmetz JP; Verghese J; Beauchet O
Eur J Neurol; 2016 Mar; 23(3):527-41. PubMed ID: 26662508
[TBL] [Abstract][Full Text] [Related]
29. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer's Disease Clinical Cohort.
Pavlik VN; Chan W; Darby E
J Alzheimers Dis; 2019; 71(2):659-669. PubMed ID: 31424408
[TBL] [Abstract][Full Text] [Related]
30. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile.
Smits LL; Pijnenburg YA; Koedam EL; van der Vlies AE; Reuling IE; Koene T; Teunissen CE; Scheltens P; van der Flier WM
J Alzheimers Dis; 2012; 30(1):101-8. PubMed ID: 22366769
[TBL] [Abstract][Full Text] [Related]
31. Relationship between small cerebral white matter lesions and cognitive function in patients with Alzheimer's disease and amnestic mild cognitive impairment.
Makino T; Umegaki H; Suzuki Y; Yanagawa M; Nonogaki Z; Nakashima H; Kuzuya M
Geriatr Gerontol Int; 2014 Oct; 14(4):819-26. PubMed ID: 24215176
[TBL] [Abstract][Full Text] [Related]
32. Cognitive trajectories preluding the onset of different dementia entities: a descriptive longitudinal study using the NACC database.
Liampas I; Dimitriou N; Siokas V; Messinis L; Nasios G; Dardiotis E
Aging Clin Exp Res; 2024 May; 36(1):119. PubMed ID: 38780681
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.
Malek-Ahmadi M; Chen K; Davis K; Belden CM; Powell J; Jacobson SA; Sabbagh MN
Alzheimers Res Ther; 2015 Jan; 7():1. PubMed ID: 26584966
[TBL] [Abstract][Full Text] [Related]
34. [Discriminatory validity and association of the mini-mental test (MMSE) and the memory alteration test (M@T) with a neuropsychological battery in patients with amnestic mild cognitive impairment and Alzheimer's disease].
Rami L; Bosch B; Valls-Pedret C; Caprile C; Sánchez-Valle Díaz R; Molinuevo JL
Rev Neurol; 2009 Aug 16-31; 49(4):169-74. PubMed ID: 19621317
[TBL] [Abstract][Full Text] [Related]
35. Differences in rate of functional decline across three dementia types.
Gill DP; Hubbard RA; Koepsell TD; Borrie MJ; Petrella RJ; Knopman DS; Kukull WA
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S63-71. PubMed ID: 23643459
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
[TBL] [Abstract][Full Text] [Related]
37. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
[TBL] [Abstract][Full Text] [Related]
38. Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease.
Kirson NY; Scott Andrews J; Desai U; King SB; Schonfeld S; Birnbaum HG; Ball DE; Kahle-Wrobleski K
J Alzheimers Dis; 2018; 61(1):295-307. PubMed ID: 29154268
[TBL] [Abstract][Full Text] [Related]
39. The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable.
Mez J; Mukherjee S; Thornton T; Fardo DW; Trittschuh E; Sutti S; Sherva R; Kauwe JS; Naj AC; Beecham GW; Gross A; Saykin AJ; Green RC; Crane PK; ; ;
Neurobiol Aging; 2016 May; 41():115-121. PubMed ID: 27103524
[TBL] [Abstract][Full Text] [Related]
40. Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains.
Smits LL; Pijnenburg YA; van der Vlies AE; Koedam EL; Bouwman FH; Reuling IE; Scheltens P; van der Flier WM
Eur Neuropsychopharmacol; 2015 Jul; 25(7):1010-7. PubMed ID: 25891378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
